Principles of K-Ras effector organization and the role of oncogenic K-Ras in cancer initiation through G1 cell cycle deregulation

References

• Papers of special note have been highlighted as:
   Google Scholar
• • of interest
   Google Scholar
• •• of considerable interest
   Google Scholar
• Ahearn IM, Haigis K, Bar-Sagi D, et al. Regulating the regulator: post-translational modification of RAS. Nat Rev Mol Cell Biol. 2012;13(1):39–51.
   Web of Science ®Google Scholar

• This is an excellent recent review uniquely detailing the post-translational modifications of Ras isoforms and how they regulate them

• Rusanescu G, Gotoh T, Tian X, et al. Regulation of Ras signaling specificity by protein kinase C. Mol Cell Biol. 2001;21(8):2650–2658.
   PubMed Web of Science ®Google Scholar
• Moodie SA, Willumsen BM, Weber MJ, et al. Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. Science. 1993;260(5114):1658–1661.
   PubMed Web of Science ®Google Scholar
• Vojtek AB, Hollenberg SM, Cooper JA. Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell. 1993;74(1):205–214.
   PubMed Web of Science ®Google Scholar
• Warne PH, Viciana PR, Downward J. Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro. Nature. 1993;364(6435):352–355.
   PubMed Web of Science ®Google Scholar
• Zhang XF, Settleman J, Kyriakis JM, et al. Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1. Nature. 1993;364(6435):308–313.
   PubMed Web of Science ®Google Scholar
• Castellano E, Downward J. RAS interaction with PI3K: more than just another effector pathway. Gene Canc. 2011;2(3):261–274.
   PubMedGoogle Scholar

•• PI3K is a major effector of Ras. Even though the review is already four years old, the information, and in particular the critical point of view that it presents is invaluable to the understanding of this key regulator, particularly considering its role in adenocarcinomas (see also reference 18)

• Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489–501.
   PubMed Web of Science ®Google Scholar
• Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11(11):761–774.
   PubMed Web of Science ®Google Scholar
• Eser S, Schnieke A, Schneider G, et al. Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer. 2014;111(5):817–822.
   PubMed Web of Science ®Google Scholar

• This review provides a nice overall view of K-Ras signaling in a disease where it contributes dominantly (the incidence of mutations is about 95%)

• Goi T, Rusanescu G, Urano T, et al. Ral-specific guanine nucleotide exchange factor activity opposes other Ras effectors in PC12 cells by inhibiting neurite outgrowth. Mol Cell Biol. 1999;19(3):1731–1741.
   PubMed Web of Science ®Google Scholar
• Linnemann T, Kiel C, Herter P, et al. The activation of RalGDS can be achieved independently of its Ras binding domain. Implications of an activation mechanism in Ras effector specificity and signal distribution. J Biol Chem. 2002;277(10):7831–7837.
   PubMed Web of Science ®Google Scholar
• Herrmann C, Horn G, Spaargaren M, et al. Differential interaction of the ras family GTP-binding proteins H-Ras, Rap1A, and R-Ras with the putative effector molecules Raf kinase and Ral-guanine nucleotide exchange factor. J Biol Chem. 1996;271(12):6794–6800.
   PubMed Web of Science ®Google Scholar
• Gentry LR, Martin TD, Reiner DJ, et al. Ral small GTPase signaling and oncogenesis: more than just 15minutes of fame. Biochim Biophys Acta. 2014;1843(12):2976–2988.
   PubMed Web of Science ®Google Scholar

• This review is unique in covering the Ral pathway. Most reviews focus on Raf and PI3K. The review also nicely details the contribution of this pathway to adenocarcinomas, which has been largely overlooked by the literature

• Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012;72(10):2457–2467.
   PubMed Web of Science ®Google Scholar

•• This paper shows a very useful compilation and analysis of Ras mutations, to which cancer they contribute and via which isoform

• Housden BE, Perrimon N. Spatial and temporal organization of signaling pathways. Trends Biochem Sci. 2014;39(10):457–464.
   PubMed Web of Science ®Google Scholar
• Vandal G, Geiling B, Dankort D. Ras effector mutant expression suggest a negative regulator inhibits lung tumor formation. PloS one. 2014;9(1):e84745.
   PubMed Web of Science ®Google Scholar
• Nussinov R, Muratcioglu S, Tsai CJ, et al. The key role of calmodulin in KRAS-driven adenocarcinomas. Mol Cancer Res. 2015;13(9):1265–1273.
   PubMed Web of Science ®Google Scholar

•• This novel review highlights the role of calmodulin/calcium in cancers of ductal tisues (lung, pancreas, colorectal, breast and more), and in particular provides a detailed mechanism how. It explains why these cancers involve particularly K-Ras4B, the only Ras isoform which binds calmodulin

• Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3(1):11–22.
   PubMed Web of Science ®Google Scholar
• Shields JM, Pruitt K, McFall A, et al. Understanding Ras: ‘it ain’t over ‘til it’s over’. Trends Cell Biol. 2000;10(4):147–154.
   PubMed Web of Science ®Google Scholar
• Muratcioglu S, Chavan TS, Freed BC, et al. GTP-dependent K-Ras dimerization. Structure. 2015;23:1325–1335.
   PubMed Web of Science ®Google Scholar

•• This paper unveils the two major dimer interfaces of K-Ras4B. This is important for understanding Ras regulation, drug discovery and nanostructures and as such has been the focus of a major drive in the community

• Nan X, Tamguney TM, Collisson EA, et al. Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway. Proc Natl Acad Sci U S A. 2015;112(26):7996–8001.
   PubMed Web of Science ®Google Scholar
• Woods D, Parry D, Cherwinski H, et al. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol. 1997;17(9):5598–5611.
   PubMed Web of Science ®Google Scholar
• Zhu J, Woods D, McMahon M, et al. Senescence of human fibroblasts induced by oncogenic Raf. Gene Dev. 1998;12(19):2997–3007.
   PubMed Web of Science ®Google Scholar
• Lin AW, Barradas M, Stone JC, et al. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Gene Dev. 1998;12(19):3008–3019.
   PubMed Web of Science ®Google Scholar
• Serrano M, Lin AW, McCurrach ME, et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997;88(5):593–602.
   PubMed Web of Science ®Google Scholar
• Xu Y, Li N, Xiang R, et al. Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence. Trends Biochem Sci. 2014;39(6):268–276.
   PubMed Web of Science ®Google Scholar

•• This is an excellent review overviewing pathways leading to senescence. A main advantage is in its providing pathway detail

• Wang W, Chen JX, Liao R, et al. Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol Cell Biol. 2002;22(10):3389–3403.
   PubMed Web of Science ®Google Scholar
• Urosevic J, Garcia-Albeniz X, Planet E, et al. Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH. Nat Cell Biol. 2014;16(7):685–694.
   PubMed Web of Science ®Google Scholar
• Neel NF, Martin TD, Stratford JK, et al. The RalGEF-Ral effector signaling network: the road less traveled for anti-Ras drug discovery. Gene Canc. 2011;2(3):275–287.
   PubMedGoogle Scholar
• Jang H, Abraham SJ, Chavan TS, et al. Mechanisms of membrane binding of small GTPase K-Ras4B farnesylated hypervariable region. J Biol Chem. 2015;290(15):9465–9477.
   PubMed Web of Science ®Google Scholar
• Tsygankova OM, Wang H, Meinkoth JL. Tumor cell migration and invasion are enhanced by depletion of Rap1 GTPase-activating protein (Rap1GAP). J Biol Chem. 2013;288(34):24636–24646.
   PubMed Web of Science ®Google Scholar
• Dong X, Tang W, Stopenski S, et al. RAP1GAP inhibits cytoskeletal remodeling and motility in thyroid cancer cells. Endocr Relat Cancer. 2012;19(4):575–588.
   PubMed Web of Science ®Google Scholar
• Qiu T, Qi X, Cen J, et al. Rap1GAP alters leukemia cell differentiation, apoptosis and invasion in vitro. Oncol Rep. 2012;28(2):622–628.
   PubMed Web of Science ®Google Scholar
• Djos A, Martinsson T, Kogner P, et al. The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma. Mol Cancer. 2012;11:40.
   PubMed Web of Science ®Google Scholar
• Fernandes MS, Carneiro F, Oliveira C, et al. Colorectal cancer and RASSF family–a special emphasis on RASSF1A. Int J Cancer. 2013;132(2):251–258.
   PubMed Web of Science ®Google Scholar
• Kuo KK, Kuo CJ, Chiu CY, et al. Quantitative proteomic analysis of differentially expressed protein profiles involved in pancreatic ductal adenocarcinoma. Pancreas. 2015. DOI:10.1097/MPA.0000000000000388.
   PubMedGoogle Scholar
• Baron B, Fujioka T, Kitagawa T, et al. Comparative proteomic analysis of two stress-management strategies in pancreatic cancer. Cancer Genomics Proteomics. 2015;12(2):83–87.
   PubMed Web of Science ®Google Scholar
• Dong Q, Zhang Y, Yang XH, et al. Serum calcium level used as a prognostic predictor in patients with resectable pancreatic ductal adenocarcinoma. Clin Res Hepatol Gastroenterol. 2014;38(5):639–648.
   PubMed Web of Science ®Google Scholar
• Bauer I, Grozio A, Lasiglie D, et al. The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses. J Biol Chem. 2012;287(49):40924–40937.
   PubMed Web of Science ®Google Scholar
• Genkinger JM, Wang M, Li R, et al. Dairy products and pancreatic cancer risk: a pooled analysis of 14 cohort studies. Ann Oncol. 2014;25(6):1106–1115.
   PubMed Web of Science ®Google Scholar
• Choi DL, Jang SJ, Cho S, et al. Inhibition of cellular proliferation and induction of apoptosis in human lung adenocarcinoma A549 cells by T-type calcium channel antagonist. Bioorg Med Chem Lett. 2014;24(6):1565–1570.
   PubMed Web of Science ®Google Scholar
• Ay AS, Benzerdjeb N, Sevestre H, et al. Orai3 constitutes a native store-operated calcium entry that regulates non small cell lung adenocarcinoma cell proliferation. PloS one. 2013;8(9):e72889.
   PubMed Web of Science ®Google Scholar
• Chung L, Phillips L, Lin MZ, et al. A novel truncated form of S100P predicts disease-free survival in patients with lymph node positive breast cancer. Cancer Lett. 2015;368(1):64–70.
   Web of Science ®Google Scholar
• Schaal C, Padmanabhan J, Chellappan S. The role of nAChR and calcium signaling in pancreatic cancer initiation and progression. Cancers (Basel). 2015;7(3):1447–1471.
   PubMedGoogle Scholar
• Liu G, Shi Z, Jiao S, et al. Structure of MST2 SARAH domain provides insights into its interaction with RAPL. J Struct Biol. 2014;185(3): 366–374.
   PubMed Web of Science ®Google Scholar
• Hwang E, Cheong HK, Ul Mushtaq A, et al Structural basis of the heterodimerization of the MST and RASSF SARAH domains in the Hippo signalling pathway. Acta Crystallogr D Biol Crystallogr. 2014;70(Pt 7):1944–1953.
   PubMed Web of Science ®Google Scholar

• The detailed structural characterization in this review is invaluable for understanding how the SARAH domains contribute to signaling

• Takahashi M, Dillon TJ, Liu C, et al. Protein kinase A-dependent phosphorylation of Rap1 regulates its membrane localization and cell migration. J Biol Chem. 2013;288(39):27712–27723.
   PubMed Web of Science ®Google Scholar
• Villalonga P, Lopez-Alcala C, Bosch M, et al. Calmodulin binds to K-Ras, but not to H- or N-Ras, and modulates its downstream signaling. Mol Cell Biol. 2001;21(21):7345–7354.
   PubMed Web of Science ®Google Scholar
• Vos MD, Martinez A, Ellis CA, et al. The pro-apoptotic Ras effector Nore1 may serve as a Ras-regulated tumor suppressor in the lung. J Biol Chem. 2003;278(24):21938–21943.
   PubMed Web of Science ®Google Scholar
• Vos MD, Ellis CA, Elam C, et al. RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J Biol Chem. 2003;278(30):28045–28051.
   PubMed Web of Science ®Google Scholar
• Elad-Sfadia G, Haklai R, Balan E, et al. Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J Biol Chem. 2004;279(33):34922–34930.
   PubMed Web of Science ®Google Scholar
• Bhagatji P, Leventis R, Rich R, et al. Multiple cellular proteins modulate the dynamics of K-ras association with the plasma membrane. Biophys J. 2010;99(10):3327–3335.
   PubMed Web of Science ®Google Scholar
• Ho A, Dowdy SF. Regulation of G(1) cell-cycle progression by oncogenes and tumor suppressor genes. Curr Opin Genet Dev. 2002;12(1):47–52.
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153–166.
   PubMed Web of Science ®Google Scholar
• Aleem E, Arceci RJ. Targeting cell cycle regulators in hematologic malignancies. Frontiers Cell Developmental Biology. 2015;3:16–16.
   PubMed Web of Science ®Google Scholar

•• This paper unveils the two major dimer interfaces of K-Ras4B. This is important for understanding Ras regulation, drug discovery and nanostructures and as such has been the focus of a major drive in the community

• Massague J. G1 cell-cycle control and cancer. Nature. 2004;432(7015):298–306.
   PubMed Web of Science ®Google Scholar
• Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Biol. 2008;9(7):517–531.
   PubMed Web of Science ®Google Scholar
• Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle (Georgetown, Tex.). 2003;2(4):339–345.
   PubMed Web of Science ®Google Scholar
• Aktas H, Cai H, Cooper GM. Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27(KIP1). Mol Cell Biol. 1997;17(7):3850–3857.
   PubMed Web of Science ®Google Scholar
• Drosten M, Dhawahir A, Sum EYM, et al. Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J. 2010;29(6):1091–1104.
   PubMed Web of Science ®Google Scholar
• Coleman ML, Marshall CJ, Olson MF. RAS and RHO GTPases in G1-phase cell-cycle regulation. Nat Rev Mol Biol. 2004;5(5):355–366.
   PubMed Web of Science ®Google Scholar
• Bertoli C, Skotheim JM, de Bruin RAM. Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Biol. 2013;14(8):518–528.
   PubMed Web of Science ®Google Scholar

•• An excellent review of the regulation of transcription in the cell cycle focusing on the key G1 phase discussed here and the S phase as well

• Dyson N. The regulation of E2F by pRB-family proteins. Gene Dev. 1998;12(15):2245–2262.
   PubMed Web of Science ®Google Scholar
• Yao G, Lee TJ, Mori S, et al. A bistable Rb-E2F switch underlies the restriction point. Nat Cell Biol. 2008;10(4):476–U255.
   PubMed Web of Science ®Google Scholar
• Weinberg RA. The retinoblastoma protein and cell-cycle control. Cell. 1995;81(3):323–330.
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Roberts JM. Inhibitors of mammalian G(1) cyclin-dependent kinases. Gene Dev. 1995;9(10):1149–1163.
   PubMed Web of Science ®Google Scholar
• Hitomi M, Yang K, Guo Y, et al. p27Kip1 and cyclin dependent kinase 2 regulate passage through the restriction point. Cell Cycle. 2006;5(19):2281–2289.
   PubMed Web of Science ®Google Scholar
• Moeller SJ, Sheaff RJ. G1 phase: components, conundrums, context. In: Kaldis P, editor. Results Probl Cell Differ. 2006;42:1–29.
   Google Scholar
• Jones SM, Kazlauskas A. Growth-factor-dependent mitogenesis requires two distinct phases of signalling. Nat Cell Biol. 2001;3(2):165–172.
   PubMed Web of Science ®Google Scholar
• Foster DA, Yellen P, Xu L, et al. Regulation of G1 cell cycle progression: distinguishing the restriction point from a nutrient-sensing cell growth checkpoint(s). Gene Canc. 2010;1(11):1124–1131.
   PubMedGoogle Scholar

• This review highlights the restriction point in deciding cell cycle progression and provides useful information

• Blagosklonny MV, Pardee AB. The restriction point of the cell cycle. Cell Cycle (Georgetown, Tex.). 2002;1(2):103–110.
   PubMed Web of Science ®Google Scholar
• Smith EJ, Leone G, DeGregori J, et al. The accumulation of an E2F-p130 transcriptional repressor distinguishes a G(0) cell state from a G(1) cell state. Mol Cell Biol. 1996;16(12):6965–6976.
   PubMed Web of Science ®Google Scholar
• Campisi J, di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Biol. 2007;8(9):729–740.
   PubMed Web of Science ®Google Scholar
• Buttitta LA, Edgar BA. Mechanisms controlling cell cycle exit upon terminal differentiation. Curr Opin Cell Biol. 2007;19(6):697–704.
   PubMed Web of Science ®Google Scholar
• Demidenko ZN, Blagosklonny MV. Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle. 2008;7(21):3355–3361.
   PubMed Web of Science ®Google Scholar
• Kyriakis JM. Thinking outside the box about Ras. J Biol Chem. 2009;284(17):10993–10994.
   PubMed Web of Science ®Google Scholar
• Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004;5(11):875–885.
   PubMed Web of Science ®Google Scholar
• Rozengurt E. Mitogenic signaling pathways induced by G protein-coupled receptors. J Cell Physiol. 2007;213(3):589–602.
   PubMed Web of Science ®Google Scholar
• McKay MM, Morrison DK. Integrating signals from RTKs to ERK/MAPK. Oncogene. 2007;26(22):3113–3121.
   PubMed Web of Science ®Google Scholar
• Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011;36(6):320–328.
   PubMed Web of Science ®Google Scholar
• Anjum R, Blenis J. The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol. 2008;9(10):747–758.
   PubMed Web of Science ®Google Scholar
• Dhillon AS, Hagan S, Rath O, et al. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279–3290.
   PubMed Web of Science ®Google Scholar
• Iwasa H, Han J, Ishikawa F. Mitogen-activated protein kinase p38 defines the common senescence-signalling pathway. Genes Cells Devoted Mol Cell Mech. 2003;8(2):131–144.
   PubMed Web of Science ®Google Scholar
• Bartkova J, Rezaei N, Liontos M, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature. 2006;444(7119):633–637.
   PubMed Web of Science ®Google Scholar
• Di Micco R, Fumagalli M, Cicalese A, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature. 2006;444(7119):638–642.
   PubMed Web of Science ®Google Scholar
• Wang X, McGowan CH, Zhao M, et al. Involvement of the MKK6-p38gamma cascade in gamma-radiation-induced cell cycle arrest. Mol Cell Biol. 2000;20(13):4543–4552.
   PubMed Web of Science ®Google Scholar
• Suram A, Kaplunov J, Patel PL, et al. Oncogene-induced telomere dysfunction enforces cellular senescence in human cancer precursor lesions. EMBO J. 2012;31(13):2839–2851.
   PubMed Web of Science ®Google Scholar
• Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell. 2010;40(2):310–322.
   PubMed Web of Science ®Google Scholar
• Sun P. Contact inhibition against senescence. Oncotarget. 2014;5(17):7212–7213.
   PubMed Web of Science ®Google Scholar
• Leontieva OV, Demidenko ZN, Blagosklonny MV. Contact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence program. Proc Natl Acad Sci U S A. 2014;111(24):8832–8837.
   PubMed Web of Science ®Google Scholar

•• This is an outstanding paper discussing how cell contact and density act to suppress senescence

• Lim KH, O’Hayer K, Adam SJ, et al. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. Curr Biol. 2006;16(24):2385–2394.
   PubMed Web of Science ®Google Scholar
• Rondaij MG, Bierings R, van Agtmaal EL, et al Guanine exchange factor RalGDS mediates exocytosis of Weibel-Palade bodies from endothelial cells. Blood. 2008;112(1):56–63.
   PubMed Web of Science ®Google Scholar
• Bhattacharya M, Anborgh PH, Babwah AV, et al. Beta-arrestins regulate a Ral-GDS Ral effector pathway that mediates cytoskeletal reorganization. Nat Cell Biol. 2002;4(8):547–555.
   PubMed Web of Science ®Google Scholar
• White MA, Vale T, Camonis JH, et al. A role for the Ral guanine nucleotide dissociation stimulator in mediating Ras-induced transformation. J Biol Chem. 1996;271(28):16439–16442.
   PubMed Web of Science ®Google Scholar
• Hannah MJ, Skehel P, Erent M, et al. Differential kinetics of cell surface loss of von Willebrand factor and its propolypeptide after secretion from Weibel-Palade bodies in living human endothelial cells. J Biol Chem. 2005;280(24):22827–22830.
   PubMed Web of Science ®Google Scholar
• Herrmann C, Martin GA, Wittinghofer A. Quantitative analysis of the complex between p21ras and the Ras-binding domain of the human Raf-1 protein kinase. J Biol Chem. 1995;270(7):2901–2905.
   PubMed Web of Science ®Google Scholar
• Geyer M, Herrmann C, Wohlgemuth S, et al. Structure of the Ras-binding domain of RalGEF and implications for Ras binding and signalling. Nat Struct Biol. 1997;4(9):694–699.
   PubMedGoogle Scholar
• D’Adamo DR, Novick S, Kahn JM, et al. rsc: a novel oncogene with structural and functional homology with the gene family of exchange factors for Ral. Oncogene. 1997;14(11):1295–1305.
   PubMed Web of Science ®Google Scholar
• Hernandez-Munoz I, Malumbres M, Leonardi P, et al. The Rgr oncogene (homologous to RalGDS) induces transformation and gene expression by activating Ras, Ral and Rho mediated pathways. Oncogene. 2000;19(23):2745–2757.
   PubMed Web of Science ®Google Scholar
• Hao Y, Wong R, Feig LA. RalGDS couples growth factor signaling to Akt activation. Mol Cell Biol. 2008;28(9):2851–2859.
   PubMed Web of Science ®Google Scholar
• Gloerich M, Bos JL. Regulating Rap small G-proteins in time and space. Trends Cell Biol. 2011;21(10):615–623.
   PubMed Web of Science ®Google Scholar
• Albright CF, Giddings BW, Liu J, et al. Characterization of a guanine nucleotide dissociation stimulator for a ras-related GTPase. EMBO J. 1993;12(1):339–347.
   PubMed Web of Science ®Google Scholar
• Matsubara K, Kishida S, Matsuura Y, et al. Plasma membrane recruitment of RalGDS is critical for Ras-dependent Ral activation. Oncogene. 1999;18(6):1303–1312.
   PubMed Web of Science ®Google Scholar
• Beranger F, Goud B, Tavitian A, et al. Association of the Ras-antagonistic Rap1/Krev-1 proteins with the Golgi complex. Proc Natl Acad Sci U S A. 1991;88(5):1606–1610.
   PubMed Web of Science ®Google Scholar
• Pizon V, Desjardins M, Bucci C, et al. Association of Rap1a and Rap1b proteins with late endocytic/phagocytic compartments and Rap2a with the Golgi complex. J Cell Sci. 1994;107(Pt 6):1661–1670.
   PubMed Web of Science ®Google Scholar
• Maridonneau-Parini I, de Gunzburg J. Association of rap1 and rap2 proteins with the specific granules of human neutrophils. Translocation to the plasma membrane during cell activation. J Biol Chem. 1992;267(9):6396–6402.
   PubMed Web of Science ®Google Scholar
• Berger G, Quarck R, Tenza D, et al. Ultrastructural localization of the small GTP-binding protein Rap1 in human platelets and megakaryocytes. Br J Haematol. 1994;88(2):372–382.
   PubMed Web of Science ®Google Scholar
• Feig LA, Urano T, Cantor S. Evidence for a Ras/Ral signaling cascade. Trends Biochem Sci. 1996;21(11):438–441.
   PubMed Web of Science ®Google Scholar
• Janosi L, Li Z, Hancock JF, et al. Organization, dynamics, and segregation of Ras nanoclusters in membrane domains. Proc Natl Acad Sci U S A. 2012;109(21):8097–8102.
   PubMed Web of Science ®Google Scholar

• An important paper which provides a molecular view of Ras nanoclusters

• Parker JA, Mattos C. The Ras-membrane interface: isoform-specific differences in the catalytic domain. Mol Cancer Res. 2015;13(4):595–603.
   Web of Science ®Google Scholar
• Mazur PK, Reynoird N, Khatri P, et al. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature. 2014;510(7504):283–287.
   PubMed Web of Science ®Google Scholar
• Ying H, DePinho RA. Cancer signaling: when phosphorylation meets methylation. Cell Res. 2014;24(11):1282–1283.
   PubMed Web of Science ®Google Scholar
• Sasaki AT, Carracedo A, Locasale JW, et al. Ubiquitination of K-Ras enhances activation and facilitates binding to select downstream effectors. Sci Signal. 2011;4(163):ra13.
   PubMed Web of Science ®Google Scholar
• Feig LA. Ral-GTPases: approaching their 15 minutes of fame. Trends Cell Biol. 2003;13(8):419–425.
   PubMed Web of Science ®Google Scholar
• Corbit KC, Trakul N, Eves EM, et al. Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein. J Biol Chem. 2003;278(15):13061–13068.
   PubMed Web of Science ®Google Scholar
• Tsai FD, Lopes MS, Zhou M, et al. K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif. Proc Natl Acad Sci U S A. 2015;112(3):779–784.
   PubMed Web of Science ®Google Scholar
• Liao J, Planchon SM, Wolfman JC, et al. Growth factor-dependent AKT activation and cell migration requires the function of c-K(B)-Ras versus other cellular ras isoforms. J Biol Chem. 2006;281(40):29730–29738.
   PubMed Web of Science ®Google Scholar
• Agell N, Bachs O, Rocamora N, et al. Modulation of the Ras/Raf/MEK/ERK pathway by Ca(2+), and calmodulin. Cell Signal. 2002;14(8):649–654.
   PubMed Web of Science ®Google Scholar
• Abraham SJ, Nolet RP, Calvert RJ, et al. The hypervariable region of K-Ras4B is responsible for its specific interactions with calmodulin. Biochemistry. 2009;48(32):7575–7583.
   PubMed Web of Science ®Google Scholar
• Lopez-Alcala C, Alvarez-Moya B, Villalonga P, et al. Identification of essential interacting elements in K-Ras/calmodulin binding and its role in K-Ras localization. J Biol Chem. 2008;283(16):10621–10631.
   PubMed Web of Science ®Google Scholar
• Ashery U, Yizhar O, Rotblat B, et al. Nonconventional trafficking of Ras associated with Ras signal organization. Traffic. 2006;7(9):119–126.
   PubMed Web of Science ®Google Scholar
• Wu LJ, Xu LR, Liao JM, et al. Both the C-terminal polylysine region and the farnesylation of K-RasB are important for its specific interaction with calmodulin. PloS one. 2011;6(7):e21929.
   PubMed Web of Science ®Google Scholar
• Sidhu RS, Clough RR, Bhullar RP. Ca2+/calmodulin binds and dissociates K-RasB from membrane. Biochem Biophys Res Commun. 2003;304(4):655–660.
   PubMed Web of Science ®Google Scholar
• Aytuna AS, Gursoy A, Keskin O. Prediction of protein-protein interactions by combining structure and sequence conservation in protein interfaces. Bioinformatics. 2005;21(12):2850–2855.
   PubMed Web of Science ®Google Scholar
• Ogmen U, Keskin O, Aytuna AS, et al. PRISM: protein interactions by structural matching. Nucleic Acids Res. 2005;33 (Web Server issue):W331–336.
   PubMed Web of Science ®Google Scholar
• Tuncbag N, Gursoy A, Nussinov R, et al. Predicting protein-protein interactions on a proteome scale by matching evolutionary and structural similarities at interfaces using PRISM. Nat Protoc. 2011;6(9):1341–1354.
   PubMed Web of Science ®Google Scholar
• Nussinov R, Ma B, Tsai CJ. A broad view of scaffolding suggests that scaffolding proteins can actively control regulation and signaling of multienzyme complexes through allostery. Biochim Biophys Acta. 2013;1834(5):820–829.
   PubMed Web of Science ®Google Scholar
• Baouz S, Jacquet E, Bernardi A, et al. The N-terminal moiety of CDC25(Mm), a GDP/GTP exchange factor of Ras proteins, controls the activity of the catalytic domain. Modulation by calmodulin and calpain. J Biol Chem. 1997;272(10):6671–6676.
   PubMed Web of Science ®Google Scholar
• Buchsbaum R, Telliez JB, Goonesekera S, et al. The N-terminal pleckstrin, coiled-coil, and IQ domains of the exchange factor Ras-GRF act cooperatively to facilitate activation by calcium. Mol Cell Biol. 1996;16(9):4888–4896.
   PubMed Web of Science ®Google Scholar
• de Hoog CL, Fan WT, Goldstein MD, et al. Calmodulin-independent coordination of Ras and extracellular signal-regulated kinase activation by Ras-GRF2. Mol Cell Biol. 2000;20(8):2727–2733.
   PubMed Web of Science ®Google Scholar
• Farnsworth CL, Freshney NW, Rosen LB, et al. Calcium activation of Ras mediated by neuronal exchange factor Ras-GRF. Nature. 1995;376(6540):524–527.
   PubMed Web of Science ®Google Scholar
• Tian X, Rusanescu G, Hou W, et al. PDK1 mediates growth factor-induced Ral-GEF activation by a kinase-independent mechanism. EMBO J. 2002;21(6):1327–1338.
   PubMed Web of Science ®Google Scholar
• Carragher NO, Fonseca BD, Frame MC. Calpain activity is generally elevated during transformation but has oncogene-specific biological functions. Neoplasia. 2004;6(1):53–73.
   PubMed Web of Science ®Google Scholar
• Wang KL, Khan MT, Roufogalis BD. Identification and characterization of a calmodulin-binding domain in Ral-A, a Ras-related GTP-binding protein purified from human erythrocyte membrane. J Biol Chem. 1997;272(25):16002–16009.
   PubMed Web of Science ®Google Scholar
• Park JB. Regulation of GTP-binding state in RalA through Ca2+ and calmodulin. Exp Mol Med. 2001;33(1):54–58.
   PubMed Web of Science ®Google Scholar
• van der Weyden L, Adams DJ. The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta. 2007;1776(1):58–85.
   PubMed Web of Science ®Google Scholar
• Volodko N, Gordon M, Salla M, et al. RASSF tumor suppressor gene family: biological functions and regulation. FEBS Lett. 2014;588(16):2671–2684.
   PubMed Web of Science ®Google Scholar
• Allen NP, Donninger H, Vos MD, et al. RASSF6 is a novel member of the RASSF family of tumor suppressors. Oncogene. 2007;26(42): 6203–6211.
   PubMed Web of Science ®Google Scholar
• Kumari G, Mahalingam S. Extracellular signal-regulated kinase 2 (ERK-2) mediated phosphorylation regulates nucleo-cytoplasmic shuttling and cell growth control of Ras-associated tumor suppressor protein, RASSF2. Exp Cell Res. 2009;315(16):2775–2790.
   PubMed Web of Science ®Google Scholar
• Song H, Kim H, Lee K, et al. Ablation of Rassf2 induces bone defects and subsequent haematopoietic anomalies in mice. EMBO J. 2012;31(5):1147–1159.
   PubMed Web of Science ®Google Scholar
• Akino K, Toyota M, Suzuki H, et al. The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology. 2005;129(1):156–169.
   PubMed Web of Science ®Google Scholar
• Kuznetsov S, Khokhlatchev AV. The growth and tumor suppressors NORE1A and RASSF1A are targets for calpain-mediated proteolysis. PloS one. 2008;3(12):e3997.
   PubMed Web of Science ®Google Scholar
• Schagdarsurengin U, Richter AM, Hornung J, et al. Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences. Mol Cancer. 2010;9:264.
   PubMed Web of Science ®Google Scholar
• Clark J, Freeman J, Donninger H. Loss of RASSF2 enhances tumorigencity of lung cancer cells and confers resistance to chemotherapy. Mol Biol Int. 2012;2012:705948.
   PubMedGoogle Scholar
• Ikeda M, Kawata A, Nishikawa M, et al. Hippo pathway-dependent and -independent roles of RASSF6. Sci Signal. 2009;2(90):ra59.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Viciana P, Sabatier C, McCormick F. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol Cell Biol. 2004;24(11):4943–4954.
   PubMed Web of Science ®Google Scholar
• Hamad NM, Elconin JH, Karnoub AE, et al. Distinct requirements for Ras oncogenesis in human versus mouse cells. Gene Dev. 2002;16(16):2045–2057.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Viciana P, Warne PH, Khwaja A, et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell. 1997;89(3):457–467.
   PubMed Web of Science ®Google Scholar
• Lambert JM, Lambert QT, Reuther GW, et al. Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism. Nat Cell Biol. 2002;4(8):621–625.
   PubMed Web of Science ®Google Scholar
• Chang LC, Chiu HM, Shun CT, et al. Mutational profiles of different macroscopic subtypes of colorectal adenoma reveal distinct pathogenetic roles for KRAS, BRAF and PIK3CA. BMC Gastroenterol. 2014;14(1):221.
   PubMed Web of Science ®Google Scholar
• Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007;7(4):295–308.
   PubMed Web of Science ®Google Scholar
• Nussinov R, Tsai CJ. ‘Latent drivers’ expand the cancer mutational landscape. Curr Opin Struct Biol. 2015;32:25–32.
   PubMed Web of Science ®Google Scholar
• Tsai CJ, Nussinov R. The free energy landscape in translational science: how can somatic mutations result in constitutive oncogenic activation? Phys Chem Chem Phys. 2014;16(14):6332–6341.
   PubMed Web of Science ®Google Scholar
• Tsai CJ, Nussinov R. A unified view of “how allostery works”. PLoS Comput Biol. 2014;10(2):e1003394.
   PubMed Web of Science ®Google Scholar
• Nussinov R, Ma B, Tsai CJ, et al. Allosteric conformational barcodes direct signaling in the cell. Structure. 2013;21(9):1509–1521.
   PubMed Web of Science ®Google Scholar
• Bardeesy N, Sharpless NE. RAS unplugged: negative feedback and oncogene-induced senescence. Cancer Cell. 2006;10(6):451–453.
   PubMed Web of Science ®Google Scholar
• Cagnol S, Rivard N. Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition. Oncogene. 2013;32(5):564–576.
   PubMed Web of Science ®Google Scholar
• Nussinov R, Jang H, Tsai CJ. Oligomerization and nanocluster organization render specificity. Biol Rev Camb Philos Soc. 2015;90(2):587–598.
   PubMed Web of Science ®Google Scholar
• Nussinov R, Jang H. Dynamic multiprotein assemblies shape the spatial structure of cell signaling. Prog Biophys Mol Biol. 2014;116(2–3):158–164.
   PubMed Web of Science ®Google Scholar
• Nussinov R, Tsai CJ, Mattos C. ‘Pathway drug cocktail’: targeting Ras signaling based on structural pathways. Trends Mol Med. 2013;19(11):695–704.
   PubMed Web of Science ®Google Scholar

• The importance of this paper is in highlighting the relevance of information of structural pathways and how this can help in designing Ras therapeutics. It argues that structural pathways provide critical information in constructing combinatorial drug libraries

• Kar G, Keskin O, Gursoy A, et al. Allostery and population shift in drug discovery. Curr Opin Pharmacol. 2010;10(6):715–722.
   PubMed Web of Science ®Google Scholar
• Greten FR. YAP1 takes over when oncogenic K-Ras slumbers. Cell. 2014;158(1):11–12.
   PubMed Web of Science ®Google Scholar
• Kapoor A, Yao W, Ying H, et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell. 2014;158(1):185–197.
   PubMed Web of Science ®Google Scholar

•• This paper observes the Yap pathway which is redundant to Ras. This is extremely important as the cell can exploit it in drug resistance

• Shao DD, Xue W, Krall EB, et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell. 2014;158(1):171–184.
   PubMed Web of Science ®Google Scholar

•• This paper also observes the Yap pathway which is redundant to Ras. This is extremely important as the cell can exploit it in drug resistance